Improving Vaccines Against Pneumococcal Disease

29 September 1996

Streptococcus pneumoniae is far and away the most common cause of invasive bacterial meningitis, which although rare is most prevalent in children and has a 20% fatality rate. As a result, meningitis is the attention-grabbing pneumococcal disease which makes headline news, but pneumococci are also a leading cause of respiratory morbidity and mortality in the developing world, as well as a common cause of glue-ear or otitis media. Now, growing antibiotic resistance in this organism is concentrating attention on the need for effective vaccination strategies to combat the infection.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Company News Directory



Companies featured in this story

More ones to watch >






Company Spotlight